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Tumour and normal tissue from 41 male cases of Wilms’ tumour were screened to determine the presence of sequence
variants in the glypican 3 (GPC3) gene. Two non-conservative single base changes were present in tumour tissue only. These
ﬁndings imply a possible role for GPC3 in Wilms’ tumour development.
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It has been known for many years that the risk of Wilm’ tumour
(WT) is greatly increased in children with certain congenital
abnormalities and syndromes, but the complexity of WT genetics
has only been recognised more recently (Hastie, 1994). Thus far
the only WT gene to be fully characterised is WT1, located on
chromosome 11p13 but deletion or mutation to WT1 is found
in only about 20% of sporadic WT (Huff, 1998). Beckwith-Wiede-
mann syndrome (BWS) is characterised by pre-and/or post-natal
overgrowth and a variety of other congenital abnormalities and
confers a greatly increased risk of WT (DeBaun and Tucker,
1998). Other overgrowth syndromes may also predispose to WT.
Numerically the most important of these is Simpson-Golabi-
Behmel syndrome (SGBS) which shows an X-linked pattern of
inheritance. WT has been noted in a number of patients with SGBS
(Xuan et al, 1994, 1999; Hughes-Benzie et al, 1996; Lindsay et al,
1997).
Constitutional deletions or mutations in the glypican 3 gene
(GPC3) at Xq26 are found in many SGBS families (Pilia et al,
1996). This suggests that deletion or mutation in GPC3 may be
involved in the development of some WT cases. The possibility
that somatic mutations to GPC3 may be present in sporadic WT
not associated with SGBS therefore also arises. To investigate this
possibility we have analysed an unselected series of WT cases, for
the presence of somatic and constitutional alterations to GPC3 in
tumour and normal tissue respectively.
MATERIALS AND METHODS
Approval for the project was given by the relevant research ethics
committees. Histopathological material from incident cases of
WT included in the Manchester Children’s Tumour Registry (Blair
and Birch, 1994) was examined. Parafﬁn blocks containing tumour
tissue and normal kidney respectively, were selected for each case.
To simplify the analysis male cases only were included in the study.
One to two 10-micron sections from each block were placed in
individual tubes and DNA extracted as described (Varley et al,
1999). Oligonucleotide primers were custom synthesised by Life
Technologies to a standard purity. Table 1 details the main
GPC3 primers used in this study. PCR reactions were carried out
using a Techne GeneE Thermal Cycler. A standard protocol of
100 m1 reactions, containing 0.5 mg of each primer, either 16
Taq buffer (Roche) or 16 TNK 100 buffer (Blanchard et al,
1993), 100 mM dNTPs and 3 units of Taq polymerase, with or
without 5% DMSO, was run for one cycle at 948C for 3 min,
followed by 38 cycles of 948C for 1 min, annealing temperature
(see Table 2) for 1 min, and 728C for 1 min. A ﬁnal extension
at 728C for 10 min was given at the end of the last cycle. Products
from the same PCR reaction could be used for both SSCP analysis
and subsequent sequencing.
Table 2 shows the primer pairs used for SSCP, providing total
coverage of the coding region of GPC3. One m1 of PCR product
was subjected to a second round of ampliﬁcation in a 10 m1 reac-
tion (10 cycles at 948C for 1 min, 508C for 1 min, and 728C for
1 min with the ﬁnal cycle having an extension time of 10 min)
as described previously (Varley et al, 1999). Initially, tumour mate-
rial only was examined. Where a variant was identiﬁed DNA from
the corresponding normal tissue was analysed and the fragment
sequenced. Controls (no DNA and normal DNA) were included
on every gel. Any samples showing abnormal band shifts were
re-analysed by repeating both ﬁrst- and second-round SSCP–
PCR reactions.
PCR products were puriﬁed using a Wizard PCR Preps DNA
Puriﬁcation System (Promega). Approximately 100 ng of this
DNA was labelled with Big Dye Terminator DNA Sequencing Kit
(ABI) using a Perkin Elmer 480 DNA Thermal Cycler and ABI
protocols and sequenced using an ABI 377 system. The splice site
prediction program made available from the Berkeley Drosophila
genome project (http://www.fruitﬂy.org/seq_tools/splice.html) was
applied routinely with any sequence variant to address the
possibility of a new splice site being created.
RESULTS
Paired tumour and normal tissue samples were available on 41
male cases. Seven different variants were detected. Variant 4 was
present in three cases but the remaining six variants were detected
in single cases only. Variants 1–5 were present in both tumour
derived and the corresponding normal DNA. Variants 6 and 7 were
detected in tumour derived material only (Figure 1).
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to a silent T–C transition in exon 7, position 1697 (all nucleotide
numbering refers to the sequence described by Huber et al, 1997).
Variant 3 is due to a silent A–G transition in exon 8 position
1823. Both variants were reported in three out of 13 ovarian cancer
cell lines, and always occur together (Lin et al, 1999). Variant 2 is
the result of a G–A transition in exon 5, position 1482, which
changes non-polar valine to non-polar methionine. We have
observed the same sequence variant in blood samples from two
out of 36 unselected breast cancer patients (i.e. 72 X chromo-
somes). Variants 4 and 5 are the result of the reduction in a run
of 16 Ts in the splice acceptor region of exon 3–15 and 14 respec-
tively. We consider variants 1–5 to be polymorphisms with no
predicted effect on splicing.
Sequencing showed variant 6 to be due to a C–T transition in
exon 3 position 558. This changes a basic histidine to an uncharged
polar tyrosine. Variant 7 is due to a G–A transition in exon 8,
position 1902. This changes the non-polar alanine to the polar
threonine. Variants 6 and 7 are tumour speciﬁc i.e. they were
present in tumour DNA but were not detected in DNA from
normal kidney and may represent somatic mutations.
DISCUSSION
GPC3 is one of six glypican genes which so far have been identiﬁed
in vertebrates. Glypicans are highly evolutionarily conserved cell
surface proteins which have a role in morphogenesis and growth
regulation. Glypican 3, encoded by the GPC3 gene, is a GPI-linked
heparan sulphate proteoglycan. It is highly expressed in embryonic
mesodermal tissues corresponding to the tissues showing over-
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Table 1 Glypican 3 (GPC3) oligonucleotides used in this study
Exon Primer Sequence
1 1B* 5'TAGGCACGCTCAAGGGAC
1F 5'TCCTAGCTCCCTGCGAAGCA
2 2A* 5'GTTTGCCCTGTTTGCCATG
2B* 5'CAAATAATGATGCCACTAAGC
3 3A* 5'GGATTTTCATGCTTTAATTTG
3B* 5'AGGTCACGTCTTGCTCCTC
3C* 5'CCTGCCTGATTCAGCCTTGGAC
3D* 5'GTTGAAAAGAGACCAAGC
3E* 5'GAGAGAATACATTCTGTCC
3F* 5'CCTCTGACAACTGTAGAC
3G 5'CCTGAAGTTCAGTAAGGACTG
3H 5'ACCATCATCAGTCCCTGGCA
3J 5'ATGTAGAGAGCACATCTGTGA
3K 5'CAAGCCTGACTCCACAAGCT
44 C 5 'CTATCATATCTGCACAAGTATC
4D 5'CAATTGTTAATTGTATTGTGGAAT
5 5A* 5'GCCTCTTATGCACAGATG
5D 5'CCTCAAATATTGCTATATGTAAC
66 C 5 'TGAGCTTGTGGTCAGTCTGA
6D 5'TCCTCTCTCTCGGTTATTTCTAC
7 7A* 5'GAAGAGCTGATGCATTCC
7C 5'CATTTGGGTCAGCACTAATCAG
8 8A* 5'GTGTTATACTGAGGCTATG
8G 5'GTGGTTCCCTTTATCGAGGA
Some denoted as * have been described previously (Huber et al, 1997). More
detailed sequence information is available with GenBank accession numbers
AF003529, Z99570, AL009174, AL008712 and AC002420.
Table 2 Details of the main primer pairs and PCR conditions used to
provide total coverage of the coding region of GPC3 for SCCP analysis
DMSO Annealing Product
Exon Primer pair Buffer (+5%) temp (8C) size (bp)
1 1B/1F Roche + 60 225
2 2A/2B Roche 7 60 329
3 3A/3J Roche 7 59 183
3K/3B Roche + 60 211
3C/3H TNK100 7 55 255
3G/3D Roche 7 58 243
3E/3F Roche 7 55 173
4 4C/4D TNK100 7 57 231
5 5A/5D Roche 7 57 200
6 6C/6D Roche 7 60 279
7 7A/7C Roche + 59 221
8 8A/8G Roche 7 60 296
TGGCATGG CGA
138N
TGGCATGG C G A
527N
TGGCAT GGCGA TGGCATG G C G A
527T Variant 7 138T Variant 7
Figure 1 Sequencing electropherograms of variants 6 and 7. Sample 138 shows a C–T transition, not present in the normal, which changes a basic
histidine to an uncharged polar tyrosine at position 558. The variant in sample 527 is a G–A transition at position 1902 which changes the non-polar alanine
to the polar threonine. Note that sample 138 is shown sequenced on the reverse strand.
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David, 2001). It is the only glypican to date for which mutations in
humans have been documented.
We have detected somatic point mutations in the GPC3 gene in
two out of 41 WT cases (4.9%). This represents the ﬁrst fully docu-
mented report of such mutations in tumour tissue and provides
evidence that disruption of the GPC3 protein may be involved in
initiation, development or progression in some Wilms’ tumours.
Support for such a role is provided by the observation that
GPC3 is expressed in WT tissue but not in the corresponding
normal kidney (Saikali et al, 2000). The 4.9% GPC3 mutation
frequency detected in the present series may be an underestimate
since the methods used did not include analysis of the promoter
region and would not have detected large deletions of GPC3 exons
which occur in some SGBS patients (Hughes-Benzie et al, 1996;
Pilia et al, 1996; Lindsay et al, 1997). Southern blotting is not
suitable for the archival material available to us, but we have
partially addressed this issue by carrying out multiplex PCR analy-
sis of GPC3 exons and a control gene for 20 of the WT samples.
Results (data not shown) showed no evidence for deletions.
The mutation in exon 8 occurs near to the C terminus in a
predicted region of glycosylphosphatidylinositol (GPI) anchorage.
A number of deletions detected in patients with SGBS also affect
exon 8 and probably prevent attachment of any product to the cell
membrane (Hughes-Benzie et al, 1996; Pilia et al, 1996; Lindsay et
al, 1997). Furthermore, the GPI-anchoring domain has been iden-
tiﬁed as critical for the induction of apoptosis in mesothelioma and
breast cancer cell lines (Gonzalez et al, 1998). The mutation in
exon 3 does not appear to be in any known functional domain
but is non-conservative and may be expected to affect protein
conformation. The ﬁve published cases of WT in patients with
SGBS in whom alterations in the GPC3 gene have been detected
were all associated with constitutional deletions in exon 1 and/or
exon 2 (Hughes-Benzie et al, 1996; Pilia et al, 1996; Lindsay et
al, 1997). Additional studies are required to establish the functional
consequences of these putative somatic mutations.
In conclusion in this preliminary study, we have identiﬁed
somatic mutations in the GPC3 gene in two of 41 cases of WT,
providing evidence of a link between developmental genes and
embryonal tumours. Further investigations of the possible role of
GPC3 in WT are indicated.
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